
News|Videos|December 5, 2025
Modernizing Kidney Stone Treatment: Devices, Data, and Clinical Impact
Author(s)Naeem Bhojani, MD, FRCSC, Karen L. Stern, MD
Fact checked by: Patrick Campbell
Explore the latest advancements in kidney stone treatment, focusing on suction technology and its impact on surgical outcomes and patient safety.
Advertisement
Advertisement
Kidney stones are an increasingly common public health problem, with notable increases observed in women1 and children.2 Myriad treatment options exist, ranging from extracorporeal shock wave lithotripsy to ureteroscopy to percutaneous nephrolithotomy. A challenge for clinicians is removing enough of a patient’s stone burden and residual fragments as possible to avoid repeat procedures.
Related to this article

Hiddo Heerspink, PharmD, PhD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack finerenone’s FIND-CKD data in FSGS.

Lesley Inker, MD, MS, joins Brendon Neuen, MBBS, PhD, to unpack GFR slope and hierarchical composite endpoints in glomerular disease trials.

Suceena Alexander, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to discuss platform trial design in IgA nephropathy and beyond.

Approval of obinutuzumab for adults with PMN follows MAJESTY, where 37% vs 6% achieved complete remission at week 104 vs tacrolimus.

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

Lawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.
Advertisement
Advertisement
